The rodent OR-I7 is an olfactory receptor exemplar activated by aliphatic aldehydes such as octanal.
Introduction
The mammalian olfactory (a.k.a. odorant) receptors (ORs) form the largest family of G-protein coupled receptors (GPCRs) in the human and rodent genomes. [1] [2] [3] Mice, for example, are predicted to have over 1000 different OR genes, while humans have approximately 390 ORs out of a total of about 825 predicted GPCR genes. Within the context of the GPCR structure, 4, 5 each OR is expected to form within its 7-transmembrane alpha helical (TM) bundle a unique binding site with distinct ligand-binding properties resulting from the convergence of receptor-specific residues, mainly from TM3, TM5, TM6 and TM7. [6] [7] [8] [9] [10] Some receptors, like the rodent I7 receptor (OR-I7; a.k.a. MOR103-15 and Olfr2), 11 which we study here, appear to be highly specific for odorant ligand traits such as functional group and carbon chain length, but others appear to lack ligand specificity, at least in vitro. 12, 13 The requirement for volatility puts a limit on an odorant's molecular weight and number of polar functional groups, but terrestrial ORs have nevertheless evolved to bind innumerable small, usually hydrophobic ligands which offer a receptor limited opportunity for hydrogen-bonding and other polar interactions. Aliphatic odorants such as monoterpenoids (e.g. geraniol), sesquiterpenoids (e.g. santalols), and those derived from fatty acid biogenic precursors (e.g. octanal) typically have only one polar functional group, and many hydrocarbons are found among fragrant natural products. The specific manner in which the ORs interact with the hydrocarbon portion of an odorant remains entirely unknown. The terpenoid, fatty acyl-derived and hydrocarbon odorants therefore present interesting molecular recognition puzzles because their odor character appears to depend heavily on attributes of their carbon skeletons, including features such as length, size and shape. Using calcium imaging of dissociated olfactory receptor neurons (ORNs, a.k.a. odorant sensory neurons, OSNs), evidence for a correlation was previously found between ligand conformational flexibility and the number of different ORs a ligand activated when the sole polar functional group (an aldehyde) and the number of carbons (eight) were kept constant.
14 This evidence suggested that for some odorants, carbon chains with more well-defined shapes activate fewer receptors than more flexible analogs, and may thereby achieve unique olfactory codes 15 by activating smaller subsets of sensory neurons which, when mature, express only one type of OR. For example, the cyclic muscone family of odorants appears to activate only one major human OR, 13, [16] [17] [18] [19] while octanal, an odorant with an acyclic, conformationally unrestricted chain, activates 33-55 rat ORs. 20 By having betterdefined shapes and also lower entropy loss upon binding, conformationally restricted ligands may be limited to binding fewer ORs than their more flexible relatives. To date, there are no atomic-level structural data on how odorants bind olfactory receptors. In this report we attempt to study the variable of carbon chain shapes in the context of a known OR-antagonist pair.
While studying conformational restriction of the octanal carbon chain as a determinant of OR-I7 activation, a relationship was previously found between restriction of the chain and whether an eight carbon aldehyde activated the receptor or bound without activation.
14 The present work is a follow-up to that study, whose findings we summarize here. Compound 1, octanal, is a natural product activating ligand, or agonist, of OR-I7. Conceptually joining octanal's third and eighth carbons, to make cyclohexylethanal (compound 2, Fig. 1 ), conformationally restricts the chain and prevents it from unfurling to an extended conformation. We found that this change converted octanal into a non-activating ligand, or antagonist (Fig. 1A ). 14 Pentanal, compound 3, which when extended has about the same chain length as 2, was also found to be an antagonist, but was less potent than 2. When two carbons were added back to 2, to make (4-ethylcyclohexyl)ethanal, compound 4, or to pentanal to make heptanal, the aldehydes regained their ability to function as agonists. These and prior findings led us to conclude that the OR-I7 receptor requires a minimum of two molecular features in a ligand, and a third feature if binding is to trigger activation. For binding, either as an agonist or antagonist, the aldehyde group is required (Fig. 1A , CHO recognition). 11, 14 Next, for binding, but not necessarily activation, an aliphatic chain of at least five carbons total (as in pentanal, e.g.) is required. 14 We refer to octanal carbons-2 through -5 or -6, as the ligand "mid-region." For aldehydes longer than hexanal, for example, the midregion connects the aldehyde to the third feature, a small hydrophobic group (e.g. carbons 7 and 8 in octanal) that must reach a putative small hydrophobic group binding pocket for OR-I7 activation. Aliphatic aldehydes shorter than the threshold of about 6.9 Å bind, but do not activate, OR-I7 and can thus function as antagonists. 14 We note that a similar dependence of activation on alkyl chain length has been found for another Class A GPCR, the cannabinoid CB1 receptor. The CB1 agonist Δ 9 -tetrahydrocannabinol (THC) contains a simple n-pentyl chain whereas the CB1 antagonist Δ 9 -tetrahydrocannabivarin (THCV) has an n-propyl chain but is otherwise identical. 21 Based on our initial short aldehyde data using rat OR-I7 there appeared to be a possible correlation between the number of carbons in the ligand's mid-region and the strength of the estimated IC 50 for antagonists that can inhibit the activation of OR-I7 by co-applied octanal. 14 In this study, to extend the previous OR-I7 findings we have made a series of new OR-I7 antagonists to probe the midregion requirements of aldehyde antagonists. Each compound was designed to have an extended length less than 6.9 Å to avoid receptor activation. We used methyl and ethyl groups and a variety of rings to increase the number of carbons within the mid-region. We find that the OR-I7 binding site in contact with the ligand's mid-region has a surprising capacity for aliphatic carbons, but prefers dense, compact rings with no branches, such as the bicyclo[2.2.2]octyl and adamantyl ring systems.
Experimental
Method to estimate the maximum extended length of aldehydes Chem3D Ultra 12.0 software (CambridgeSoft) was used. The structure of the aldehyde was drawn in its most extended conformation. The energy was minimized using the MM2 force field. The length was then measured from the carbonyl carbon to the most remote carbon.
Chemical synthesis and characterization
The synthesis and characterization of the tested compounds is described in detail in the ESI. † 14 A small alkyl group such as ethyl, extending beyond ≈6.9 Å from the aldehyde, is required for receptor activation. Compounds 1 and 4 are agonists; 2 and 3 are antagonists. (B) Compounds designed in this study for antagonist structure-activity relationship analysis. Estimated lengths are for the most extended conformations after energy minimization.
Hana3A GloSensor cAMP assay
The GloSensor cAMP Assay System (Promega) was used according to the manufacturer's instructions with slight modifications. A plasmid encoding Rho-tagged mouse OR-I7 (80 ng per well) was transfected into the Hana3A cell line in 96-well plate (Biocoat; Becton Dickinson Biosciences) format along with plasmids encoding the human receptor trafficking protein, RTP1S (10 ng per well), type 3 muscarinic acetylcholine receptor (M3-R) (10 ng per well), and pGloSensor TM-22F (10 ng per well). Then, 18 to 24 h following transfection, cells were loaded with 2% GloSensor reagent for 2 h and treated with compounds in a total volume of 74 µL. Luminescence was measured using a Polarstar Optima plate reader (BMG) with a time interval of 90 seconds per well. Data were analyzed and IC 50 s were estimated using Prism 5.0 and Microsoft Excel. Responses over t = 3-7.5 minutes were summed, base-lined, normalized, and plotted versus odorant concentration.
Homology model construction and ligand docking
A mouse OR-I7 homology model was constructed beginning with a previously published rat OR-I7 ortholog model. 22 The initial rat model was based on crystallographic data taken from rhodopsin PDB entry 1U19. The mouse model included the following rat-to-mouse ortholog substitutions (single-letter amino acid abbreviations; underscore indicates a predicted helical position in TM2-TM7, superscripts are BallesterosWeinstein numbering 23 for TM residues): V26A 24 The ligand binding pocket of the mOR-I7 was predicted using the SiteMap module of Maestro software package (Version 10.2, Schrödinger, LLC, New York, NY, 2015). Protonation states of amino acids were assigned by using the PROPKA module, followed by structural relaxation using the preparation wizard tool. 25 The docking configurations of the ligands were analyzed by using the Glide module of Maestro. 26 Short (20 ns) molecular dynamics simulations were performed using the CHARMM force field, as implemented in NAMD. 27 During simulations, both octanal and the antagonists were observed to sample the different aldehyde group orientations shown in Fig. 5 .
Results and discussion

Antagonist design
To probe the structural requirements of the OR-I7 ligand midregion, but without extending into the receptor's small hydrophobic binding pocket beyond 6.9 Å from the aldehyde group, we began with two previously identified antagonists, pentanal (IC 50 460 μM in rat OR-I7) and cyclohexylethanal (compound 2, IC 50 37 μM, also in rat OR-I7). 14 As shown in Fig. 1B, carbons were added incrementally to pentanal at carbon-3, to produce compounds 5-8. (Compound 5 is the only chiral compound in the set and was made in racemic form.) The three ethyl groups radiating from carbon-3 in 8 were also conformationally restricted by incorporating them into the bicyclo[2.2.2]octyl ring system (compound 9). For the set based on antagonist 2, carbons were added incrementally at carbon-3 to make 10 and 11. Compound 11 can be viewed as an incompletely restricted version of compound 9. Lastly, the adamantyl ring in 12, which is larger than 2 by four carbons but, like compound 9, is highly restricted and has no protruding small alkyl groups, was used to probe the size limit of the mid-region.
Synthesis of OR-I7 antagonists
The synthesis and characterization of designed antagonists 5-12 is described in detail in the ESI. †
Antagonist testing
The IC 50 values previously estimated for compounds 2 and 3 were obtained in dissociated rat ORNs infected with an adenovirus vector carrying the rat OR-I7. 14, 28 Despite one seminal report that the mouse ortholog, which has 15 amino acid differences overall but only 2 predicted to be in the TM2-TM7 helical regions, prefers heptanal over octanal when expressed in HEK293 cells, 29 we and others have found that both rat and mouse orthologs are aldehyde-specific and respond similarly to octanal and heptanal. 30, 31 Here, we opted to continue using the mouse ortholog but as expressed in Hana3A cells. The Hana3A system consists of specially modified HEK293T cells, including the odorant receptor specific G-protein, G olf , and avoids the need to use live rodents. 32 We found that in these cells the mouse OR-I7 gave a more consistent octanal-induced cAMP response than rat OR-I7. To minimize the possibility of any differential evaporation among the ligands, which vary in molecular weight, we also switched from the original luciferase reporter gene system to the GloSensor™ reporter, which detects the second messenger cAMP as it is produced in response to agonist-receptor binding. 33 The response vs. time plot for different concentrations of octanal applied alone is shown in Fig. 2A . To be an antagonist, a compound must not activate the receptor, and using this reporter system we confirmed that compound 2 is not a mouse OR-I7 agonist (Fig. 2B ). When compound 2 was co-applied at increasing concentrations with a constant concentration of octanal (5 μM), the response to octanal was reduced in a dosedependent manner (Fig. 2C) . This result showed that 2 antagonized the activation of mouse OR-I7 by octanal, as it did in the rat homolog expressed in neurons.
14 To obtain an OR-I7 response vs. concentration plot for estimating IC 50 s, we summed the reporter response over the period of highest cAMP production, from 3 to 7.5 minutes following addition of the odorant(s) to the stimulation medium (Fig. 2C ). This measurement allowed us to estimate the EC 50 of octanal (0.7 μM, confidence interval 0.35-1.4 μM) and then to estimate the IC 50 values for the designed aldehyde antagonists. We note that day-to-day variation in the Hana3A cells, plasmid transfection efficiency and the cAMP assay response prevented the calculation of absolute IC 50 values, but relative efficacies remained consistent during preliminary testing. For this reason, we evaluated the candidate antagonists side-by-side with previously studied antagonists 2 and 3 to obtain the most accurate structure-activity comparison. Compounds grouped within Fig. 3 and 4 were tested with six replicates in the same experiment. Antagonists bind to their receptors without activating them. The first step in evaluating the new compounds was therefore to see whether any of the proposed antagonists, which are all shorter than 6.9 Å, activated mouse OR-I7. The results, summarized in Fig. 3A and 4A showed that none of these aldehydes activated Hana3A cells expressing the mouse OR-I7. These experiments provided further evidence that the aldehyde length vs. activation relationship previously found in the rat OR-I7 also held for the mouse OR-I7 ortholog.
Observing the response to 5 μM octanal in the presence of increasing concentrations of each inhibitor allowed us to estimate the IC 50 of each compound, subject to the limitations of the assay described above. Inhibition plots are shown for compounds 3, and 5-9 (Fig. 3B) , and for compounds 2 and 9-12 (Fig. 4B) . The estimated IC 50 values are listed below the structures in the C panels of the same figures. Within each figure, all compounds were tested side-by-side on the same day on cells from the same Hana3A culture.
Structure activity relationship of the antagonists
Pentanal, 3, but not butanal, was previously shown to function as a weak rat OR-I7 antagonist, 14 while compound 2, which is about the same length as pentanal but has eight carbons, was eight-fold more potent as an antagonist. One simplistic interpretation of this difference is that increasing the number of carbons on the aldehyde buries more hydrophobic surface area upon binding OR-I7 (i.e. a favorable hydrophobic effect contribution) and also increases the van der Waals contact with the part of the receptor binding site in contact with the ligand's mid-region. As shown in Fig. 3 , we tested this possibility by adding carbons to pentanal, beginning at carbon-3 rather than carbon-2 so as not to risk interfering with aldehyde recognition. 11 Adding one carbon to make compound 5 increased potency 5-fold, but additional carbons progressively decreased potency (compounds 6, 7, 8) until the three alkyl groups of compound 8 were tied back into the conformationally restricted bicyclo[2.2.2]octyl ring system (compound 9), which was the most potent antagonist in this series. Thus, adding one carbon to carbon-3 was favorable but additional carbons were unfavorable unless they were conformationally restricted in the bicyclo[2.2.2]octyl ring system. We used a similar approach beginning with antagonist 2, and a similar trend was observed: the methyl and ethyl groups of 10 and 11, respectively, were unfavorable, but tying compound 11's ethyl group back, as in compound 9, was once again favorable in comparison (Fig. 4) . We expanded the size of the bicyclo[2.2.2]octyl ring system − without adding methyl or ethyl groups and without exceeding 6.9 Å in length − by attaching the adamantyl group to ethanal (compound 12). This aldehyde, which was noticed to have a distinct camphoraceous odor, was 3-fold weaker in potency than 9, suggesting that while the OR-I7 binding site mid-region can accommodate this large ring system, it may be approaching the site's size limit.
In combination with previous reports on the rodent OR-I7, 11, 14, 20, 22, 31, 34, 35 our results are consistent with the view that the part of the OR-I7 binding site in contact with the ligand's mid-region has evolved to accommodate carbon chains with unbranched alkyl chains, i.e. a chain of methylene groups, such as carbons-3 through -6 of octanal. This interpretation suggests that the small alkyl protrusions of compounds 6, 7, 8, 10 and 11 may be interpreted by the receptor as alkyl chain branches, which are not found on the typical fatty acyl chain aldehyde odorants that OR-I7 is known to detect.
11
Thus, the middle of the OR-I7 site accommodates a chain of methylene groups passing through it, but anchored at one end by the aldehyde recognition site and, for activation only, at the other end by the small hydrophobic group binding site. The ability to accommodate the bicyclo[2.2.2]octyl system may reflect accommodation of a "jump rope" movement of the octanal's methylene groups between the anchors. An apparent exception to the unbranched chain preference was compound 5, whose single 3-methyl group improved potency compared to pentanal. Compound 5 is identical to the first five carbons in the carbon chain of the terpene citronellal. Interestingly, citronellal, which has an aldehyde group and a length exceeding 6.9 Å, is almost as good a rat OR-I7 agonist as octanal. 11 We suggest that the OR-I7 features that allow citronellal binding in the mid-region also allow compound 5 to bind − but as an antagonist because its chain does not extend beyond the 6.9 Å threshold required for activation. 14 The idea that shortened forms of good OR-I7 agonists make good OR-I7 antagonists (compare 5 with citronellal, and 2 with 4) raises the possibility that the binding site's mid-region is the same for agonists and antagonists alike, and the ligand does not change its location during activation. Alternatively, longer aldehydes may be able to move into a different location where they stabilize the active conformation of the receptor. Without structural information it is impossible to discern between these scenarios. Overall, these data support an interpretation where OR-I7 detects unbranched aliphatic aldehydes and citronellal-like terpene aldehydes, but when the chain is shorter than about 6.9 Å, binding fails to stabilize the activated form of the receptor and the ligand acts as an antagonist.
Structural model of the mouse OR-I7 binding site
We previously built a rhodopsin-based homology model of the unactivated rat OR-I7 and predicted an orthosteric binding site by looking for voids large enough to accommodate octanal. 22 To understand the in vitro data presented above, we adapted this model to the mouse I7 ortholog. The ligand binding sites for aldehydes 2, 8, 9, 10 and octanal were predicted using the SiteMap module of the Maestro software package. The predicted ligand binding site, modeled using compound 10, is shown in relation to the overall predicted receptor structure in Fig. 5A . The site is in the upper half of the receptor (closer to the extracellular side) and formed by TM3-TM6. The site is approximately the same binding site predicted for octanal in the rat I7 ortholog and that found experimentally for retinal in rhodopsin (see the ESI Fig. S5 † for a  comparison) . 22 In Fig. 5A which correspond in MOR256-3 to F104 (Fig. 5B-E) .
Hydrogen-bonding interactions with the aldehyde were predicted for these two tyrosines and K164 4.60 , a protonated amino acid residue that is also capable of forming a hydrogen bond with Y264 6.55 and a salt-bridge with the negatively charged D204 5.39 . Based on this model, we speculate that the conformationally flexible ethyl groups found in relatively lower potency ligands like 8 (e.g. Fig. 5C ) and 11 sterically interfere with some of the hydrophobic residues lining the site, e.g. 
Conclusions
The new aldehyde odorants studied here were designed to probe the carbon chain requirements for antagonizing the mouse OR-I7 receptor. The results show that the receptor prefers chains of methylene groups, disfavors branches except for a single methyl on carbon-3 and can accommodate a surprisingly large number of carbons (e.g. ten in adamantyl) as long as they are part of conformationally constrained ring system like cyclohexyl, bicyclo[2.2.2]octyl or adamantyl. Thus, in the context of antagonist ligands, the part of the receptor in contact with the midregion imposes shape selectivity for compact carbon rings. In the context of an agonist, the ligand mid-region has to also serve to spatially orient the two end groups − the aldehyde and last two carbons of octanal, separated optimally by five carbons − as required for activation. A homology model predicts the location of the antagonist binding site, which is close to the ligand site predicted for several other ORs and rhodopsin.
